AGIO רווחיות מכירות לפי רווח גולמי Agios Pharmaceuticals Inc

Adjusted gross margin demonstrates business efficiency, with the metric holding at 90.00. Agios Pharmaceuticals (AGIO) dominates the treatment of rare anemias due to low demand elasticity and innovations in cellular metabolism. Growth is driven by the expanded application of Pyrukynd and licensing payments for vorasidenib. Stable cash flow and royalties from oncology drugs fully cover the company's capital expenditures.
פילוחי מדדים פיננסיים ומדדי שוק עבור agios.com (AGIO)

Amidst the restructuring of Agios Pharmaceuticals (AGIO) following the spin-off of its oncology division, the gross margin chart reflects the efficiency of cost management for the production of rare disease treatments. This indicator measures the portion of revenue remaining after direct production costs, allowing investors to assess the business's pricing power and its ability to generate profit despite a highly concentrated portfolio.